--- title: Why Diverse Clinical Trials Yield Smarter, Safer Science | Acclinate description: Explore why diverse clinical trials lead to smarter, safer science—and how Acclinate’s trust-first approach makes research more accurate and inclusive. image: https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Why-Diverse-Clinical-Trials-Yield-Smarter%2c-Safer-Science.jpg --- [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate-logo.png?width=2000&height=497&name=Acclinate-logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [eDICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [Contract Research Organizations](https://www.acclinate.com/solutions/for-cros) - [Partners](https://www.acclinate.com/solutions/community-partners) - Company - [About Us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [News](https://news.acclinate.com) - Resources - [Resource Library](https://www.acclinate.com/resources) - [Blog](https://blog.acclinate.com) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [Glossary](https://www.acclinate.com/glossary) - [FAQ](https://www.acclinate.com/faq) - [Talk to Our Team](https://info.acclinate.com/get-in-touch) [![Talk to Our Team](https://no-cache.hubspot.com/cta/default/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302.png)](https://cta-redirect.hubspot.com/cta/redirect/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302) [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate_Logo.png?width=500&height=149&name=Acclinate_Logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [**NOWINCLUDED**Acclinate’s B2C community platform ](https://www.acclinate.com/products/nowincluded-the-community) - [**e-DICT**Acclinate’s patented AI-powered technology ](https://www.acclinate.com/products/e-dict) - Solutions - [**Pharmaceutical Companies**Community-driven recruitment and real-world insights to support diverse, compliant clinical trials. ](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [**Contract Research Organization (CRO)**Scalable patient engagement and recruitment solutions that reduce risk and improve enrollment timelines. ](https://www.acclinate.com/solutions/for-cros) - [**Partners**Trusted partnerships that connect research opportunities with the communities they aim to serve. ](https://www.acclinate.com/solutions/community-partners) - Company - [**About us**We help clinical research teams reach diverse communities, build trust, and improve trial participation. ](https://www.acclinate.com/about) - [**Careers**Join a mission-driven team advancing inclusive clinical research and community-powered health innovation. ](https://www.acclinate.com/careers) - Resources - [**Resources Hub** ](https://www.acclinate.com/resources) - [**Glossary** ](https://www.acclinate.com/glossary) - [**Press Kit** ](https://www.acclinate.com/press-kit) - [**Events** ](https://www.acclinate.com/events) - [**Blog** ](https://blog.acclinate.com/) - [**News** ](https://news.acclinate.com/) - [![](https://cdn.prod.website-files.com/695fbca039298e2117988a78/69e7b588548c7ad7bd8ab0bc_9dd915489696393dc63d7785ee2e52c7_Question%20mark%20image.png) **FAQs** ](https://www.acclinate.com/faq) - [ Contact Us ](https://www.acclinate.com/contact-us) Stay up to date Get news directly in your inbox Topic All - [Affective Trust ](https://blog.acclinate.com/tag/affective-trust) - [Announcement ](https://blog.acclinate.com/tag/announcement) - [Clinical Research Software ](https://blog.acclinate.com/tag/clinical-research-software) - [Clinical Trial Recruitment Strategies ](https://blog.acclinate.com/tag/clinical-trial-recruitment-strategies) - [Community ](https://blog.acclinate.com/tag/community) - [Diversity in Clinical Trials ](https://blog.acclinate.com/tag/diversity-in-clinical-trials) - [e-DICT™ ](https://blog.acclinate.com/tag/e-dict) - [FDA Diversity Plan ](https://blog.acclinate.com/tag/fda-diversity-plan) - [FDA Guidance: Diversity in Clinical Trials ](https://blog.acclinate.com/tag/fda-guidance-diversity-in-clinical-trials) - [Health Equity ](https://blog.acclinate.com/tag/health-equity) - [Partnerships ](https://blog.acclinate.com/tag/partnerships) - [Representation in Healthcare ](https://blog.acclinate.com/tag/representation-in-healthcare) [Diversity in Clinical Trials](https://blog.acclinate.com/topic/diversity-in-clinical-trials) # Why Diverse Clinical Trials Yield Smarter, Safer Science Explore why diverse clinical trials lead to smarter, safer science—and how Acclinate’s trust-first approach makes research more accurate and inclusive. ![Why Diverse Clinical Trials Yield Smarter, Safer Science](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Why-Diverse-Clinical-Trials-Yield-Smarter%2c-Safer-Science.jpg) Clinical Trial Diversity: What Does It Really Mean? Clinical trials are critical for evaluating the safety and effectiveness of medical devices and pharmaceutical products. The results of trials guide t... Read More ![ Acclinate](https://blog.acclinate.com/hubfs/69b96486c4b036c19f462c19_acclinate-logo.png) [Acclinate](https://blog.acclinate.com/author/acclinate) Acclinate turns trust and data into better representation. Share this Post: [**](https://www.facebook.com/sharer/sharer.php?u=https://blog.acclinate.com/why-diverse-clinical-trials-yield-smarter-safer-science) [**](https://twitter.com/home?status=https://blog.acclinate.com/why-diverse-clinical-trials-yield-smarter-safer-science) [** ](https://www.linkedin.com/shareArticle?mini=true&url=https://blog.acclinate.com/why-diverse-clinical-trials-yield-smarter-safer-science&title=Why%20Diverse%20Clinical%20Trials%20Yield%20Smarter,%20Safer%20Science%20|%20Acclinate) Stay up to date Get news directly in your inbox **Key Takeaways and Learnings**  - Diverse clinical trials yield smarter, safer science by making results more generalizable and interventions more effective. - Racial and ethnic disparities in research undermine trial validity, limit innovation, and widen health inequities. - Inclusive trial design isn’t just ethical—it delivers business and scientific ROI by improving outcomes and expanding market reach. - [Learn how equity-driven strategies improve trial success from the ground up with our comprehensive guide.](https://info.acclinate.com/ebook-ultimate-guide-to-advancing-health-equity-in-clinical-trials)    When clinical research fails to represent the real-world population, it doesn't only miss the mark ethically. It detracts from scientific value. When conducted effectively, diverse clinical trials help generate accurate, generalizable, and actionable results that lead to safer, more effective treatments for everyone.  Yet, [racial and ethnic disparities in research remain stubbornly persistent](https://www.kff.org/racial-equity-and-health-policy/issue-brief/racial-and-ethnic-disparities-in-access-to-medical-advancements-and-technologies/#:~:text=Access%20barriers%2C%20lack%20of%20information,in%20participating%20in%20clinical%20trials.). Populations most at risk of chronic disease and adverse outcomes are often the least represented in studies designed to help them. And when those populations are overlooked, science suffers.  Let’s explore why more representative research makes for better medicine—and how an inclusive, trust-driven approach helps clinical trials evolve into smarter, safer science. [![Download Now – Before You Recruit: The Ultimate Guide to Advancing Health Equity in Clinical Trials](https://no-cache.hubspot.com/cta/default/19943632/interactive-188916301454.png) ](https://blog.acclinate.com/hs/cta/wi/redirect?encryptedPayload=AVxigLLR3lr1pnHTeA3DsTD1o0xsNvQJ8%2FuNAhBTuZCtnEkC7%2BbXkQjXf8%2FhFec7KuuC7l%2FIiiwvThbyBZZyQyixVpIH31dCT8qnHzkrkmWYyvRlo2YhEsdFlHz%2F0QuV%2BexHPkbaBD8HonSEoiWepjDpnofWa7qUvRJPiLVTZLQgHTSUgRabKoLjaF3r18Bp8TyS1PnsVUP%2Bb4Sz5NNpARd7lY6aZoQwVdfk6MHGZNAT%2FH9P7wPw5XcniOlLfT5Q0TKxyg%3D%3D&webInteractiveContentId=188916301454&portalId=19943632) ## Representation Improves Relevance and Reliability Representation in clinical trials directly impacts the quality of the evidence generated. Human biology is anything but uniform. Variables like genetic ancestry, environmental exposure, and social determinants of health all shape how individuals respond to medications and interventions.  When trial participant pools lack diversity, the findings become less reliable for underrepresented groups. And there are tangible effects. Let’s look at Albuterol as an example. This commonly prescribed bronchodilator for asthma has been [shown to be less effective in individuals of African American and Puerto Rican descent](https://www.statnews.com/2019/03/26/asthma-african-americans-precision-medicine/) compared to other populations.  With [non-Hispanic Black Americans three times as likely to die of asthma](https://minorityhealth.hhs.gov/node/39/revisions/39/view), the stakes are high. Without inclusive trial design, research findings risk being both inaccurate and inequitable.  That’s why policy from the American Medical Association (AMA) now explicitly calls for improved equity in clinical research. A [recent update from the AMA](https://www.ama-assn.org/press-center/ama-press-releases/ama-adopts-new-policy-create-equity-clinical-trials-and-research) outlines a clear path toward more inclusive trial design—recognizing that failure to engage diverse communities can limit innovation and perpetuate disparities in care. [Learn our three key steps for engaging communities of color—genuinely and effectively](https://info.acclinate.com/3-steps-to-engage-communities-of-color). ## **The Consequences of Racial and Ethnic Disparities in Research**  Historically marginalized communities—particularly Black and Brown populations—have faced generations of systemic medical harm, leading to deep mistrust in research. That mistrust, paired with a lack of outreach and infrastructure in these communities, has contributed to persistent underrepresentation.  But exclusion doesn’t only harm the excluded. It jeopardizes the entire clinical research ecosystem.  Poor representation can lead to:  - **Ineffective therapies** that fail large swaths of the population. - **Higher adverse event rates** due to untested pharmacogenomic variables. - **Delayed regulatory approvals** or labeling revisions due to post-market safety issues. - **Limited market success** for new drugs that haven’t proven benefit across demographics.  In essence, non-representative trials are bad science and bad business. A drug that works in one group but not another—especially in a global or U.S.-based market—risks litigation, recalls, or worse: **loss of public trust**.  ## **Inclusive Trial Design**** Yields More Actionable Insights**  Inclusion isn’t a compromise, but a catalyst for innovation. When research reflects real-world demographics, researchers can uncover critical differences in how diseases progress, how drugs metabolize, and which interventions offer the greatest benefit to specific populations.  Inclusive trial design enables:  - **More robust subgroup analysis**, so clinicians can personalize treatment decisions. - **Improved post-market surveillance**, thanks to better anticipation of variation in response. - **Wider approval potential**, since regulatory bodies increasingly favor evidence that reflects population-level health.  This approach extends beyond advancing health equity to accelerate scientific accuracy. And when trials are designed with inclusion in mind from the start, the downstream benefits multiply: more seamless market rollouts, fewer compliance risks, and better returns on investment.  ## **Building Trust Is Not Optional—It’s Foundational**  Representation in research doesn’t begin with recruitment. It begins with trust.  Acclinate’s [Affective Trust Framework](https://blog.acclinate.com/overcome-clinical-trial-recruitment-challenges-start-with-affective-trust) acknowledges that people don’t participate in trials only because they’re asked. They participate when they feel seen, respected, and empowered. That kind of trust can’t be built overnight, nor can it be outsourced.  Where many initiatives focus on cognitive trust—facts, figures, incentives—Acclinate focuses on affective trust: human relationships grounded in cultural relevance, lived experience, and consistent presence in community spaces.  Our engagement strategies are connection-based, not transaction-based. By listening first and acting in partnership, we help dismantle barriers to participation that traditional recruitment efforts can’t reach.  ## **From Data to Action: The Role of Technology**  Trust must lead to action—and action must be measurable. That’s where our technology comes in.  Acclinate’s e-DICT™ platform uses predictive analytics to identify individuals who are both eligible for and likely to engage in specific research opportunities. These insights go beyond basic demographics to factor in nuanced community dynamics and historical context. Our Site Engagement Index (SEI) adds another layer of intelligence, helping sponsors and CROs evaluate trial site readiness through the lens of equity-forward engagement.  Together, these tools allow us to guide partners toward more inclusive outreach, smarter follow-up, and ultimately, better trial performance.  Our community platform, NOWINCLUDED, also plays a central role. It provides a culturally safe digital space where Black and Brown individuals can access trusted health information, share stories, and learn about clinical research in ways that feel relevant—not extractive.  ## **The Acclinate Difference: Equity From the Ground Up**  Acclinate doesn’t “plug into” a trial at the last minute. We partner upstream—well before recruitment begins—to help clinical research sponsors:  - **Design more inclusive protocols** - **Strengthen site selection through our SEI insights** - **Engage communities with culturally grounded content** - **Track and optimize representation in real time**  We’ve seen how equity-forward strategies drive better results. In one [recent initiative](https://www.acclinate.com/expanding-representation-in-copd-research), our approach helped a sponsor surpass their enrollment goals for COPD research by identifying trusted community venues, delivering personalized outreach, and maintaining strong participant relationships throughout the trial lifecycle. When equity is built in, not bolted on, everyone benefits—from the individuals who gain access to care to the sponsors who produce more effective, evidence-based therapies. ## **Ready for Research That Reflects the Real World?** The future of clinical research depends on inclusion—not as a nice-to-have, but as a foundational principle. If your organization is ready to conduct research that’s smarter, safer, and more representative, Acclinate is here to help.  Whether you're a sponsor, CRO, or healthcare leader, we bring both the heart and the tools to make equity actionable.  Want to dive deeper into the benefits of equity-forward approaches to clinical research? [Schedule a 1:1 meeting with our team](https://www.acclinate.com/request-a-demo). ## Recent Posts [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [ Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) June 25, 2026 3 Min Read Drug development economics are changing. Sponsors are increasingly relying on a single pivotal trial to support approval. Though the goal of this appr... Read More [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [ Clinical Trial Generalizability: What Regulators Will Scrutinize Next ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) June 25, 2026 3 Min Read For years, generalizability was framed as a methodological concern. Reviewers debated whether results could reasonably extend beyond a trial’s enrolle... Read More [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [ Site Engagement Index (SEI): Measuring What Actually Builds Trust ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) June 25, 2026 3 Min Read Clinical research lacks anything but metrics. Enrollment targets, site activation timelines, and digital engagement rates are tracked closely across s... Read More [![](https://blog.acclinate.com/hubfs/Imported_Blog_Media/6567a9f90c0cf111067913e2_Merck%20Pop%20Up2.png) ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) [ Acclinate to support Merck's oncology clinical trials ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) June 24, 2026 1 Min Read Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to h... Read More [![Why Trial Diversity Is Now a Risk Management Strategy](https://blog.acclinate.com/hubfs/Why-Trial-Diversity-Is-Now-a-Risk-Management-Strategy.jpg) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [ The New Control Lever: Why Trial Diversity Is Now a Risk Management Strategy ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) March 2, 2026 3 Min Read For years, conversations around trial diversity were framed as ethical or reputational concerns. That framing no longer reflects regulatory reality. Read More [![Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity](https://blog.acclinate.com/hubfs/AdobeStock_470269560.webp) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [ Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) February 16, 2026 3 Min Read Clinical research equity efforts originate with good intentions. But they often hit a roadblock in practice: communities are asked to participate in h... Read More [![How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust](https://blog.acclinate.com/hubfs/AdobeStock_1631551849.webp) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [ How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) February 9, 2026 3 Min Read Reaching underrepresented communities in healthcare research has never been simple. Participation decisions are shaped by lived experience, historical... Read More [![Data-Driven Inclusion](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Acclinate-Data-Driven-Inclusion.jpg) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [ Data-Driven Inclusion: Predictive Analytics for Trial Enrollment ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) February 2, 2026 2 Min Read Subpar enrollment remains one of the most common causes of trial delays. But sponsors often miss a key factor: underrepresentation. Lack of diversity ... Read More [![Exploring Diversity in Clinical Research With Acclinate](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Exploring-Diversity-in-Clinical-Research-With-Acclinate.jpg) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [ Exploring Diversity in Clinical Research With Acclinate ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) January 26, 2026 3 Min Read Diversity in clinical research remains a widely discussed goal, yet progress has been uneven. Trials still grapple with subpar representation, limited... Read More [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) June 25, 2026 Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World Read More ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) June 25, 2026 Clinical Trial Generalizability: What Regulators Will Scrutinize Next Read More ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) June 25, 2026 Site Engagement Index (SEI): Measuring What Actually Builds Trust Read More ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) ![Woman wearing Acclinate Shirt](https://blog.acclinate.com/hs-fs/hubfs/layer1_image.webp?width=1600&height=1068&name=layer1_image.webp) ![Medical Research Software e-DICT](https://blog.acclinate.com/hs-fs/hubfs/layer2_image.webp?width=885&height=885&name=layer2_image.webp) ![layer2.2_image](https://blog.acclinate.com/hs-fs/hubfs/layer2.2_image.webp?width=1505&height=1197&name=layer2.2_image.webp) ![layer3_image](https://blog.acclinate.com/hs-fs/hubfs/layer3_image.webp?width=1600&height=1067&name=layer3_image.webp) ## Ready to Measure Your True Impact? Partner with Acclinate to turn mission into measurable, data-driven action. [ Get Started ](https://www.acclinate.com/contact-us) [![Acclinate Logo Reversed](https://blog.acclinate.com/hs-fs/hubfs/footer_logo.png?width=1600&height=398&name=footer_logo.png "Acclinate Logo Reversed")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [e-DICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [CROs](https://www.acclinate.com/solutions/for-cros) - [Community Partners](https://www.acclinate.com/solutions/community-partners) - Resources - [Resources Hub](https://www.acclinate.com/resources) - [Glossary](https://www.acclinate.com/glossary) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [News](https://news.acclinate.com/) - [Blog](https://blog.acclinate.com/) - [FAQs](https://www.acclinate.com/faq) - Company - [About us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [Contact Us](https://www.acclinate.com/contact-us) - Follow Us - [** Linkedin](https://www.linkedin.com/company/acclinateinc/) - [Privacy Policy](https://www.acclinate.com/privacy) - [Terms of Service](https://www.acclinate.com/terms-of-use-acclinate) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Acclinate", "url" : "https://blog.acclinate.com/author/acclinate" }, "dateModified" : "2026-06-18T19:55:46.785Z", "datePublished" : "2025-08-27T13:15:00.000Z", "headline" : "Why Diverse Clinical Trials Yield Smarter, Safer Science | Acclinate", "image" : [ "https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Why-Diverse-Clinical-Trials-Yield-Smarter%2c-Safer-Science.jpg" ], "mainEntityOfPage" : { "@id" : "https://blog.acclinate.com/why-diverse-clinical-trials-yield-smarter-safer-science", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.acclinate.com/hubfs/Acclinate-logo.png" }, "name" : "Acclinate" } } ```